European Leukemia Net (ELN) divided CN-AML patients into the ELN favorable or ELN intermediate-I genetic categories, according to the mutation of CEBPA, NPM1 and FLT3-ITD [7]. This evidence concerns the gene FLT3 and acute myeloid leukemia.